Sophie M L Neuen, Daan R M G Ophelders, Helene Widowski, Matthias C Hütten, Tim Brokken, Charlotte van Gorp, Peter G J Nikkels, Carmen A H Severens-Rijvers, Mireille M J P E Sthijns, Clemens A van Blitterswijk, Freddy J Troost, Vanessa L S LaPointe, Shahab Jolani, Christof Seiler, J Jane Pillow, Tammo Delhaas, Niki L Reynaert, Tim G A M Wolfs
BACKGROUND: Perinatal inflammation increases the risk for bronchopulmonary dysplasia in preterm neonates, but the underlying pathophysiological mechanisms remain largely unknown. Given their anti-inflammatory and regenerative capacity, multipotent adult progenitor cells (MAPC) are a promising cell-based therapy to prevent and/or treat the negative pulmonary consequences of perinatal inflammation in the preterm neonate. Therefore, the pathophysiology underlying adverse preterm lung outcomes following perinatal inflammation and pulmonary benefits of MAPC treatment at the interface of prenatal inflammatory and postnatal ventilation exposures were elucidated...
December 2024: Regenerative Therapy